Bioscience lines up 3 new drugs
Thai pharmaceutical maker Siam Bioscience Group plans to produce and sell three new drugs for complicated diseases -- cancer, kidney failure and autoimmune diseases -- by 2022 both domestically and abroad.
The drugs carry a cheaper price tag than imported pharmaceuticals.
Managing director Songpon Deechongkit said the company has developed drugs for diseases such as erythropoietin for chronic renal failure patients and filgrastim for cancer patients receiving chemotherapy.